Nerviano Medical Sciences Receives Approval From the FDA to Enter Phase I Clinical Trials for Their Polo Like Kinase (PLK) Inhibitor

    NERVIANO, Italy, May 13 /CNW/ - The FDA has approved an Investigational
New Drug (IND) application by Nerviano Medical Sciences to begin a phase I
clinical study with its selective PLK-1 small molecule inhibitor for the
treatment of cancer. PLK-1 is a mitotic kinase required for the proliferation
of cancer cells. This new compound is orally bioavailable, highly efficient
and well tolerated in preclinical models of cancer after repeated dosing. This
unique inhibitor adds another promising candidate to the pipeline of
innovative cell cycle targets with different mechanisms of action in clinical
development which have been discovered and developed by NMS. These include
inhibitors of CDK, Aurora and CDC-7. An IND for an inhibitor of CDC-7 was
approved by the FDA in January this year and the first patients were treated
with the compound in April. NMS CDK and Aurora inhibitors are in phase I and
II clinical development, respectively, and are starting to show promising
activity in specific patient populations.
    The clinical development path foresees application of the NMS PLK-1
inhibitor in solid and hematological indications. "I am pleased to see the
second IND approval this year and I highly appreciate the consistent delivery
of high quality clinical candidates by the Nerviano site" comments Dr.
Francesco Colotta, VP R&D at NMS.

    Nerviano Medical Sciences (NMS)

    Nerviano Medical Sciences is the largest pharmaceutical R&D facility in
Italy and one of the largest oncology-focused, integrated discovery and
development companies in Europe. Research activities in Nerviano generate on
average two clinical candidate molecules per year. NMS takes advantage of
strategic alliances with biotechnology as well as pharmaceutical companies to
secure its long term business sustainability. The Company has already
finalized partnerships with major companies such as Pfizer Inc., Bristol-Myers
Squibb Co., Genentech Inc. as well as with several biotech companies and
academic institutions.

For further information:

For further information: Nerviano Medical Sciences, Maria D'Acquino, tel
+39-0331-581013, mob. +39-335-1863051,

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890